Ncardia (www.ncardia.com) has been established following the merger of Pluriomics and Axiogenesis. The privately held company with operations in Europe and the US, produces and commercializes high-quality, fully functional hiPSC derived cardiovascular and neuronal cell types and develops and realizes electrophysiology, biochemistry and contraction based assays for predictive safety pharmacology, toxicology testing and drug efficacy screenings.
Ncardia builds the foundation to become the trusted leader in hiPSC based drug discovery solutions.
The Pluriomics team took part in the Venture Challenge Spring 2009.
Image source: https://ncardia.com/why-ncardia/